Cell Reports Medicine (journal) Archive — Page 1 of 1

September 28, 2026

California firm licenses ‘potent’ anti-measles antibodies from Vanderbilt Health for development, clinical testing

The human monoclonal antibodies were isolated from two individuals who had been infected by measles. Further development and clinical testing could lead to the first monoclonal antibody therapy against the highly infectious respiratory virus.

By Bill Snyder
(Adobe Stock)
January 16, 2026

Vanderbilt Health team finds potent antibody that neutralizes two dangerous viruses

The single administration of an antibody that provides cross-protection against both RSV and hMPV infection could provide logistical and economic advantages over the need to develop and administer multiple virus-specific monoclonal antibodies.

By Bill Snyder
December 19, 2024

Proteomic signature a key to early detection of fatty liver disease: study

Currently, methods to detect early, obesity-related accumulation of fat in the liver other than a liver biopsy — the surgical removal of liver tissue for microscopic examination — are limited. But there is hope.

By Bill Snyder
November 8, 2024

People with schizophrenia show distinct brain activity when faced with conflicting information

Researchers introduce a biomarker to indicate whether someone is struggling with the inflexible thinking associated with the disorder.

By Joseph Caputo
February 21, 2024

International genetic study of glaucoma implicates vascular and cancer-related genes

An international genetic study using multiancestry biobanks has identified novel genetic locations associated with primary open-angle glaucoma, the most common type of glaucoma and the leading cause of irreversible blindness globally.

By Leigh MacMillan
November 6, 2023

Children’s antibodies highly potent against COVID-19: study

Reporting Nov. 6 in Cell Reports Medicine, Ivelin Georgiev, PhD, and colleagues demonstrated that antibodies isolated from children’s blood samples displayed high levels of neutralization and potency against variants of the COVID-19 virus, SARS-CoV-2, even when the children had not previously been exposed to or vaccinated against those variants.

By Bill Snyder